206 related articles for article (PubMed ID: 11316859)
21. Oral Delivery of Nanoparticles Carrying Ancestral Uricase Enzyme Protects against Hyperuricemia in Knockout Mice.
Tran L; Das S; Zhao L; Finn MG; Gaucher EA
Biomacromolecules; 2023 May; 24(5):2003-2008. PubMed ID: 37126604
[TBL] [Abstract][Full Text] [Related]
22. Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein.
Tong M; Wang S; Luan J; Xie Q; Wang L; Shen X; Xiong S
Int J Biol Macromol; 2024 Jun; 269(Pt 1):131989. PubMed ID: 38697425
[TBL] [Abstract][Full Text] [Related]
23. Preparation of PEGylated uricase attached magnetic nanowires and application for uric acid oxidation.
Kilimci U; Uygun DA
J Biotechnol; 2023 Aug; 373():12-19. PubMed ID: 37343601
[TBL] [Abstract][Full Text] [Related]
24. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
Mandell BF; Yeo AE; Lipsky PE
Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
[TBL] [Abstract][Full Text] [Related]
25. Urat1-Uox double knockout mice are experimental animal models of renal hypouricemia and exercise-induced acute kidney injury.
Hosoyamada M; Tsurumi Y; Hirano H; Tomioka NH; Sekine Y; Morisaki T; Uchida S
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):543-549. PubMed ID: 27906636
[TBL] [Abstract][Full Text] [Related]
26. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
Abuchowski A; Karp D; Davis FF
J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
[TBL] [Abstract][Full Text] [Related]
27. Use of the uricase-inhibited rat as an animal model in toxicology.
Stavric B; Nera EA
Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
[TBL] [Abstract][Full Text] [Related]
28. The case for uricase in gout.
Pay S; Terkeltaub AR
Curr Rheumatol Rep; 2003 Jun; 5(3):213-4. PubMed ID: 12744813
[No Abstract] [Full Text] [Related]
29. Phylogenetic Articulation of Uric Acid Evolution in Mammals and How It Informs a Therapeutic Uricase.
Li Z; Hoshino Y; Tran L; Gaucher EA
Mol Biol Evol; 2022 Jan; 39(1):. PubMed ID: 34718698
[TBL] [Abstract][Full Text] [Related]
30. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
Lipsky PE; Calabrese LH; Kavanaugh A; Sundy JS; Wright D; Wolfson M; Becker MA
Arthritis Res Ther; 2014 Mar; 16(2):R60. PubMed ID: 24588936
[TBL] [Abstract][Full Text] [Related]
31. Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.
Savoca KV; Davis FF; Palczuk NC
Int Arch Allergy Appl Immunol; 1984; 75(1):58-67. PubMed ID: 6746105
[TBL] [Abstract][Full Text] [Related]
32. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
33. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
[TBL] [Abstract][Full Text] [Related]
34. Molecular Elucidation of a Urate Oxidase from
Chiu YC; Hsu TS; Huang CY; Hsu CH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070642
[TBL] [Abstract][Full Text] [Related]
35. Uricase deficiency causes mild and multiple organ injuries in rats.
Fan N; Yu Y; Li L; Xia H; Dong X; Li Y; Chen H; Duan W
PLoS One; 2021; 16(8):e0256594. PubMed ID: 34437605
[TBL] [Abstract][Full Text] [Related]
36. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Tan PK; Farrar JE; Gaucher EA; Miner JN
Mol Biol Evol; 2016 Sep; 33(9):2193-200. PubMed ID: 27352852
[TBL] [Abstract][Full Text] [Related]
37. Learning how and when to employ uricase as bridge therapy in refractory gout.
Terkeltaub R
J Rheumatol; 2007 Oct; 34(10):1955-8. PubMed ID: 17924606
[No Abstract] [Full Text] [Related]
38. Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine).
Schiavon O; Caliceti P; Ferruti P; Veronese FM
Farmaco; 2000 Apr; 55(4):264-9. PubMed ID: 10966157
[TBL] [Abstract][Full Text] [Related]
39. Hypouricaemic effect after oral administration in chickens of polyethylene glycol-modified uricase entrapped in liposomes.
Nishida Y; Kamatani N; Miyamoto T
J Pharm Pharmacol; 1984 May; 36(5):354-5. PubMed ID: 6145782
[TBL] [Abstract][Full Text] [Related]
40. Update on emerging urate-lowering therapies.
Chohan S; Becker MA
Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
